To include your compound in the COVID-19 Resource Center, submit it here.

AZ replants R&D roots in China, goes all-in on innovation

AstraZeneca throws weight behind China innovation while several peers focus on commercialization

In a big week for MNCs in China, AstraZeneca defined the latest move in its China strategy with an ‘all-in’ approach to innovation that goes full throttle by fostering R&D, AI and company formation.

As MNCs twist and turn on how best to participate in China’s growing biopharma sector and tap its increasingly important market, AstraZeneca plc (LSE:AZN; NYSE:AZN) is charting a different course from some its peers.

AZ’s Nov. 6 announcement of a $1 billion-targeted fund to invest in innovative healthcare companies in or focused on China, coupled with a new R&D center, an AI center and a slew of licensing deals, sees the company take an active role in fostering the growth of the emerging ecosystem.

“The new fund will inject vitality into the small

Read the full 1241 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE